Bellerophon Therapeutics
Founded Year
2009Stage
IPO | IPOTotal Raised
$80MDate of IPO
2/13/2015Market Cap
0.10BStock Price
9.07About Bellerophon Therapeutics
Bellerophon Therapeutics (NASDAQ: BLPH) is a clinical-stage biotherapeutics company. The company is focused on developing innovative products combining novel drugs and devices in the treatment of cardiopulmonary and cardiac diseases. Bellerophon's mission is to develop well-studied molecules deployed through innovative delivery systems to treat diseases with significant unmet clinical need.
Missing: Bellerophon Therapeutics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Bellerophon Therapeutics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Bellerophon Therapeutics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Bellerophon Therapeutics is included in 1 Expert Collection, including Biopharma Tech.
Biopharma Tech
15,795 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Bellerophon Therapeutics Patents
Bellerophon Therapeutics has filed 8 patents.
The 3 most popular patent topics include:
- Respiratory therapy
- Lung disorders
- Respiratory physiology
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
8/29/2018 | Cardiac anatomy, Cardiovascular physiology, Congenital heart defects, Cardiology, Angiology | Application |
Application Date | 8/29/2018 |
|---|---|
Grant Date | |
Title | |
Related Topics | Cardiac anatomy, Cardiovascular physiology, Congenital heart defects, Cardiology, Angiology |
Status | Application |
Latest Bellerophon Therapeutics News
Mar 31, 2023
Bellerophon Therapeutics press release (NASDAQ: BLPH ): FY GAAP EPS of -$2.08 misses by $0.06. As of December 31, 2022, the Company had unrestricted cash and cash equivalents of $6.9 million, compared to unrestricted cash and cash equivalents of $24.7 million on December 31, 2021. Recommended For You
Bellerophon Therapeutics Frequently Asked Questions (FAQ)
When was Bellerophon Therapeutics founded?
Bellerophon Therapeutics was founded in 2009.
Where is Bellerophon Therapeutics's headquarters?
Bellerophon Therapeutics's headquarters is located at 184 Liberty Corner Road, Warren.
What is Bellerophon Therapeutics's latest funding round?
Bellerophon Therapeutics's latest funding round is IPO.
How much did Bellerophon Therapeutics raise?
Bellerophon Therapeutics raised a total of $80M.
Who are the investors of Bellerophon Therapeutics?
Investors of Bellerophon Therapeutics include Venrock, 5AM Ventures, New Mountain Capital, Ikaria and ARCH Venture Partners.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.